Androgens, Estrogens, Hypogonadism, Testosterone
Conditions
Brief summary
This is a prospective biobank set up to collect serum from patients with disorders associated with changes in androgens, estrogens or sex hormone-binding globulin (SHBG), before and/or after treatment.
Detailed description
In vitro cell-based bioassays may be a technique to measure serum androgen or estrogen bioactivity. In this study investigators are collecting serum (and if possible, urine) samples from different cohorts of patients, before and/or after treatment. The aim is to measure androgens, estrogens and SHBG as well as in vitro bioactivity with newly developed cell-based bioassays, and to compare different techniques to each other as well as to clinical endpoints available in the patient's Electronic Health Record.
Interventions
OTHERSerum (with or without urine) samples
Sponsors
Universitaire Ziekenhuizen KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Known or expected medical condition affecting androgens, estrogens or SHBG
Exclusion criteria
* Inability to provide written informed consent * Known or suspected bloodborne infectious diseases (e.g. HIV, viral hepatitis etc.) * Anemia (\<11 g/dL hemoglobin) or being a Jehovah's Witness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Testosterone bioequivalents (in nanomolar) | second blood sample at time of clinical follow-up (between 3 weeks and 1 year interval) |
| Estradiol bioequivalents (in picomolar) | second blood sample at time of clinical follow-up (between 3 weeks and 1 year interval) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total serum testosterone (in nanomolar) | second blood sample at time of clinical follow-up (between 3 weeks and 1 year interval) | Measured by immunoassay or liquid chromatography tandem mass spectrometry (LC-MS/MS) |
| Calculated free and bioavailable testosterone (in nanomolar) | second blood sample at time of clinical follow-up (between 3 weeks and 1 year interval) | — |
| Total serum SHBG (in nanomolar) | second blood sample at time of clinical follow-up (between 3 weeks and 1 year interval) | Measured by immunoassay |
| Total serum estradiol (in picomolar) | second blood sample at time of clinical follow-up (between 3 weeks and 1 year interval) | Measured by immunoassay or LC-MS/MS |
| Calculated free and bioavailable estradiol (in picomolar) | second blood sample at time of clinical follow-up (between 3 weeks and 1 year interval) | — |
Outcome results
None listed